Diuretic Dose and NYHA Functional Class Are Independent Predictors of Mortality in Patients With Transthyretin Cardiac Amyloidosis

Richard K Cheng, Wayne C Levy, Alexi Vasbinder, Sergio Teruya, Jeffeny De Los Santos, Douglas Leedy, Mathew S Maurer, Richard K Cheng, Wayne C Levy, Alexi Vasbinder, Sergio Teruya, Jeffeny De Los Santos, Douglas Leedy, Mathew S Maurer

Abstract

Background: With increasing diagnoses and available treatment options for transthyretin amyloidosis cardiomyopathy (ATTR-CM), risk stratification of ATTR-CM patients is imperative.

Objectives: We hypothesized that diuretic dose and New York Heart Association (NYHA) functional class are independent predictors of mortality in ATTR-CM and would be incrementally additive to existent risk scores.

Methods: Consecutive ATTR-CM patients referred to a single center were identified. Adjusted Cox proportional hazards models determined the association between diuretic dose (furosemide equivalent in mg/kg) at time of diagnosis and the primary outcome of all-cause mortality. The incremental value of adding diuretic dose and NYHA functional class to existing ATTR-CM risk scores was assessed for discrimination and calibration.

Results: 309 patients were identified, with mean age 73.2 ± 9.8 years, 84.1% male, and 66% wild type. Daily mean diuretic dose was 0.6 ± 1.0 mg/kg and significantly associated with all-cause mortality (unadjusted hazard ratio: 2.12 per 1-mg/kg increase, [95% confidence interval: 1.71 to 2.61] and fully adjusted hazard ratio: 1.43 [95% confidence interval: 1.06 to 1.93]). Testing previously published ATTR risk scores, adding diuretic dose as categories (0 mg/kg, >0 to 0.5 mg/kg, >0.5 to 1 mg/kg, and >1 to 2 mg/kg) improved the area under the curve of the Mayo risk score from 0.693 to 0.767 and the UK risk score from 0.711 to 0.787 while preserving calibration. Adding NYHA functional class further improved the area under the curve to 0.798 and 0.816, respectively.

Conclusions: Diuretic dose and NYHA functional class are independent predictors of mortality in ATTR-CM patients and provide incremental value to existing ATTR-CM risk scores.

Keywords: cardiac amyloidosis; heart failure; transthyretin.

Figures

Graphical abstract
Graphical abstract
Figure 1
Figure 1
Kaplan-Meier Curves for Freedom From All-Cause Mortality (A) Kaplan-Meier curves are shown for diuretic dose categories. (B) New York Heart Association functional class; (C) Mayo risk score categories; (D) UK risk score categories; and (E) Seattle Heart Failure Model (SHFM) score rounded to the nearest integer. For each model, comparison between groups was statistically significant with log-rank p < 0.001.
Figure 2
Figure 2
Time-Dependent ROC for All-Cause Mortality (A) Receiver-operating characteristic (ROC) curves are shown. Mayo risk score alone, Mayo score with addition of diuretic dose, and Mayo score with diuretic dose + New York Heart Association (NYHA) functional class. Adding diuretic dose to the Mayo score increased the area under the curve (AUC) from 0.693 to 0.767 and additionally adding NYHA functional class, increased it to 0.798. (B) UK risk score alone, UK score with addition of diuretic dose, and UK score with diuretic dose + NYHA functional class. Adding diuretic dose to the UK score increased the AUC from 0.711 to 0.787 and additionally adding NYHA functional class, increased it to 0.816.
Figure 3
Figure 3
Kaplan-Meier Curves for Freedom From All-Cause Mortality for the Fully Adjusted Models After Adding Diuretic Dose and NYHA Functional Class The final models were each divided into 3 risk groups (1 to 3, 4 to 6, and 7 to 9 points). (A) Mayo score + diuretic dose + NYHA functional class. (B) UK score + diuretic dose + NYHA functional class. For each model, comparison between groups was statistically significant with log-rank p < 0.001.
Central Illustration
Central Illustration
Incremental Benefit of Adding Diuretic Dose and New York Heart Association Functional Class to Existing Transthyretin Amyloidosis Cardiomyopathy Risk Models for All-Cause Mortality Adding diuretic dose + New York Heart Association (NYHA) functional class to the Mayo transthyretin amyloidosis (ATTR) score improved the time-dependent area under the curve (AUC) from 0.693 to 0.798. Adding diuretic dose + NYHA functional class to the UK ATTR score improved the time-dependent AUC from 0.711 to 0.816.

References

    1. Ruberg F.L., Grogan M., Hanna M., Kelly J.W., Maurer M.S. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73:2872–2891.
    1. Grogan M., Scott C.G., Kyle R.A. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68:1014–1020.
    1. Gillmore J.D., Damy T., Fontana M. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39:2799–2806.
    1. Felker G.M., O'Connor C.M., Braunwald E. Heart Failure Clinical Research Network I. Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? Circ Heart Fail. 2009;2:56–62.
    1. Ahmed A., Husain A., Love T.E. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J. 2006;27:1431–1439.
    1. Mielniczuk L.M., Tsang S.W., Desai A.S. The association between high-dose diuretics and clinical stability in ambulatory chronic heart failure patients. J Card Fail. 2008;14:388–393.
    1. Levy W.C., Mozaffarian D., Linker D.T. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006;113:1424–1433.
    1. Weber M., Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart. 2006;92:843–849.
    1. Lilleness B., Ruberg F.L., Mussinelli R., Doros G., Sanchorawala V. Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis. Blood. 2019;133:215–223.
    1. Uno H., Cai T., Tian L., Wei L. Evaluating prediction rules for t-year survivors with censored regression models. J Am Stat Assoc. 2007;102:527–537.
    1. Pencina M.J., D'Agostino R.B., Sr., Steyerberg E.W. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30:11–21.
    1. May S., Hosmer D.W. A simplified method of calculating an overall goodness-of-fit test for the Cox proportional hazards model. Lifetime Data Anal. 1998;4:109–120.
    1. Eshaghian S., Horwich T.B., Fonarow G.C. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol. 2006;97:1759–1764.
    1. Hasselblad V., Gattis Stough W., Shah M.R. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail. 2007;9:1064–1069.
    1. Francis G.S., Benedict C., Johnstone D.E. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD) Circulation. 1990;82:1724–1729.
    1. Gottlieb S.S., Brater D.C., Thomas I. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation. 2002;105:1348–1353.
    1. Klein L., O'Connor C.M., Leimberger J.D. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation. 2005;111:2454–2460.
    1. Dorbala S., Ando Y., Bokhari S. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol. 2019;26:2065–2123.
    1. Bokhari S., Castano A., Pozniakoff T., Deslisle S., Latif F., Maurer M.S. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6:195–201.
    1. Castano A., Haq M., Narotsky D.L. Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol. 2016;1:880–889.
    1. Hutt D.F., Fontana M., Burniston M. Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid. Eur Heart J Cardiovasc Imaging. 2017;18:1344–1350.
    1. Kristen A.V., Scherer K., Buss S. Noninvasive risk stratification of patients with transthyretin amyloidosis. J Am Coll Cardiol Img. 2014;7:502–510.
    1. Martinez-Naharro A., Kotecha T., Norrington K. Native T1 and extracellular volume in transthyretin amyloidosis. J Am Coll Cardiol Img. 2019;12:810–819.
    1. Kreusser M.M., Volz M.J., Knop B. A novel risk score to predict survival in advanced heart failure due to cardiac amyloidosis. Clin Res Cardiol. 2019;109:700–713.
    1. Cappelli F., Martone R., Gabriele M. Biomarkers and prediction of prognosis in transthyretin-related cardiac amyloidosis: direct comparison of two staging systems. Can J Cardiol. 2020;36:424–431.
    1. Maurer M.S., Schwartz J.H., Gundapaneni B. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007–1016.
    1. Kazi D.S., Bellows B.K., Baron S.J. Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy. Circulation. 2020;141:1214–1224.

Source: PubMed

3
Prenumerera